Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs
Open Access
- 7 June 2017
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 17 (1) , 147
Abstract
Coronary bioresorbable scaffolds (BRS) were developed to overcome the limitations of standard metallic stents, especially to address late events after percutaneous coronary interventions. The aim of this meta-analysis was to evaluate the efficacy and safety of BRS, compared with Everolimus-eluting stents (EES), using the data available from randomized trials, with a focus on long-term outcomes. Published randomized trials comparing BRS to EES for the treatment of coronary artery disease were searched for within PubMed, Cochrane Library and Scopus electronic databases up to April 4th 2017. The summary measure used was odds ratio (OR) with 95% confidence intervals. A total of 5 studies were eligible, including 5219 patients. At 2 years, BRS was associated with higher rates of target lesion failure (9.4% vs 7.2%; OR = 1.33; 95% CI 1.07 to 1.63; p = 0.008) and device thrombosis (2.3% vs 0.7%; OR = 3.22; 95% CI 1.86 to 5.57; p < 0.0001) compared with EES. The incidence of both early (within 30 days after implantation, 1.1% vs 0.5%, OR 1.97, 95% CI 1.02 to 3.81; p = 0.05) and very-late device thrombosis (>1 year, 0.6% vs 0.1%, OR 4.03, 95% CI 1.37 to 11.82; p = 0.01) was higher with BRS compared with EES. BRS may be associated with worse two-years clinical outcomes compared with EES in patients with coronary artery disease.Keywords
This publication has 34 references indexed in Scilit:
- Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system (WOLFIE study): a two-centre prospective comparisonThe International Journal of Cardiovascular Imaging, 2015
- Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-AnalysisPLOS ONE, 2015
- Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary SyndromesJACC: Cardiovascular Interventions, 2015
- Optical coherence tomography evaluation of overlapping everolimus-eluting bioresorbable vascular scaffold implantation guided by enhanced stent visualization systemInternational Journal of Cardiology, 2015
- Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registryEuroIntervention, 2015
- Neointimal Proliferation Is Associated With Clinical Restenosis 2 Years After Fully Bioresorbable Vascular Scaffold ImplantationCirculation: Cardiovascular Imaging, 2014
- Left radial access for percutaneous coronary procedures: From neglected to performer? A meta-analysis of 14 studies including 7603 proceduresInternational Journal of Cardiology, 2014
- Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery StenosisJACC, 2011
- Bioabsorbable Coronary StentsCirculation: Cardiovascular Interventions, 2009
- A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trialThe Lancet, 2008